檢索結果 - Li-Qing Kang

Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia 由 Li-Yun Chen, Li-Qing Kang, Hai-Xia Zhou, Han-Qing Gao, Xue-Fei Zhu, Nan Xu, Lei Yu, De-Pei Wu, Sheng-Li Xue, Ai-Ning Sun

獲取全文

CAR-T cell therapy followed by allogenic hematopoietic stem cell transplantation yielded comparable outcome between Ph like ALL and other high-risk ALL 由 Hai-ping Dai, Dan-qing Kong, Hong-jie Shen, Wei Cui, Qian Wang, Zheng Li, Jia Yin, Li-qing Kang, Lei Yu, De-pei Wu, Xiao-wen Tang

獲取全文

Secondary donor-derived humanized CD19-modified CAR-T cells induce remission in relapsed/refractory mixed phenotype acute leukemia after allogeneic hematopoietic stem cell transpla... 由 Meng-Yun Li, Zhi-Hong Lin, Ming-Ming Hu, Li-Qing Kang, Xiao-xia Wu, Qi-wei Chen, Xin Kong, Jian Zhang, Hui-Ying Qiu, De-Pei Wu

獲取全文

CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial 由 Jia Yin, Qing-Ya Cui, Hai-Ping Dai, Chang-Ju Qu, Zheng Li, Li-Qing Kang, Wei Cui, Xiao-Peng Tian, Xia-Ming Zhu, Lei Yu, De-Pei Wu, Xiao-Wen Tang

獲取全文

Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL 由 Yan Qiu, Chao-Ling Wan, Ming-Zhu Xu, Hai-Xia Zhou, Mei-Jing Liu, Wen-Jie Gong, Li-Qing Kang, Ai-Ning Sun, Lei Yu, De-Pei Wu, Chong-Sheng Qian, Sheng-Li Xue

獲取全文

Safe and potent anti‐CD19 CAR T‐cells with shRNA‐IL‐6 gene silencing element in patients with refractory or relapsed B‐cell acute lymphoblastic leukemia 由 Jin‐Feng Ma, Jia‐Wei Yan, Mei‐Jing Liu, Chun‐Long Yan, Xiao‐Wen Tang, Hui‐Ying Qiu, Miao Miao, Yue Han, Li‐Min Li, Li‐Qing Kang, Nan Xu, Zhou Yu, Jing‐Wen Tan, Hong‐Jia Zhu, Xu Jia, Zhi‐Zhi Zhang, Miao Wang, Hai‐Ping Dai, Lei Yu, Sheng‐Li Xue, De‐Pei Wu, Wen‐Jie Gong

獲取全文